Findit, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020
March 10, 2021
Share
Findit, Inc. announced earnings results for the full year ended December 31, 2020. For the full year, the company announced total revenue was USD 404,392 compared to USD 478,060 a year ago. Operating loss was USD 215,648 compared to USD 209,567 a year ago. Net loss was USD 84,604 compared to USD 208,467 a year ago.
BioRegenx, Inc., formerly Findit, Inc., operates as a holding company. The Company specializes in acquiring intellectual property (IP) and companies engaged in regenerative biotherapeutics and anti-aging research. Its primary focus involves acquiring and developing non-invasive medical and wellness devices capable of efficiently recording, storing, and analyzing datasets. The Companyâs patented technologies and solutions include GlycoCheck, a high-definition video imaging that analyzes five parameters of microvascular health non-invasively with an under the tongue test using patented technology; Endocalyx Pro, an all-natural, plant-based patented nutraceutical shown to restore, regenerate, and protect microvascular health. Clinically tested in multiple double-blind placebo studies, and DocSun, an artificial intelligence using three advanced facial recognition technologies that analyzes 21 vital signs and health indicators without physical contact.